Is UPL's worst phase finally behind it?

Summary: UPL has been through one of the toughest phases in its history. Debt pressures, margin stress, shaken confidence, you name it. Now, with balance sheets healing, is the worst truly behind it? Here’s what has changed, what hasn’t, and whether this recovery has real legs. The market has begun to look kindly upon UPL again. The stock is now trading close to its all-time high, which is striking for a business whose past two years have been among its most difficult. UPL, once a beloved chemical bet, saw its earnings weaken sharply, margins compress, with soaring debt and credit rating downgrades. But there’s a growing belief now that the company has moved past its most fragile phase. Here’s a look at what went wrong in the past and how the business is winning back market favour: One acquisition that changed it all UPL built its place among the global agrochemical elites steadily over decades through a mix of organic expansion and acquisitions. This helped it evolve from an Indian generics manufacturer into one of the world’s largest crop protection companies with operations across more than 130 countries. One defining step in this journey was the acquisition of Arysta LifeScience in FY19. The deal lifted UPL’s business profile, adding branded formulations, deeper farmer relationships and a strong presence in Latin America, which is now its largest market with a 38 per cent revenue share for the first half of FY26. Strategically, the acquisition made sense. Financially, it changed UPL’s risk profile overnight and increased leverage to astonishing levels. UPL’s debt-to-equity ratio rose sharply from about 0.7 times in FY18 to nearly 2 times in FY19, while gross debt levels increased more than fourfold. At the t

This article was originally published on January 04, 2026.